Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2305213 | 0.92 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL95459 | 0.91 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL2536584 | 0.83 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13708645 | 0.82 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1477302 | 0.82 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8660420 | 0.82 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6569206 | 0.82 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL123652 | 0.81 | NPC1 (0.79) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL14145483 | 0.80 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3442327 | 0.80 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| CN-101489555-A | Nf-kappa | OTSUKA PHARMA CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007119600-A9 | CARBAZOLE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007119600-A1 | CARBAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| WO-2003097618-A1 | MORPHOLINYLMETHYLUREAS CCR-3 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | RAB9A 3886/4885NPC1 2361/4885SMN1; SMN2 3998/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | RAB9A 2273/4885NPC1 2922/4885SMN1; SMN2 3084/4885 |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | RAB9A 2274/4885NPC1 1159/4885SMN1; SMN2 3569/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | RAB9A 2471/4885NPC1 1195/4885SMN1; SMN2 3448/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | RAB9A 2273/4885NPC1 2922/4885SMN1; SMN2 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.